Sun Yamin, Wang Min, Lin Wenchao, Dong Wei, Xu Jianguo
Research Institute of Public Health, Nankai University, Tianjin, PR China.
Research Center for Functional Genomics and Biochip, Tianjin, PR China.
J Biosaf Biosecur. 2023 Mar;5(1):14-20. doi: 10.1016/j.jobb.2023.01.002. Epub 2023 Jan 25.
On December 7, 2022, China adjusted public health control measures, there have been widespread of SARS-CoV-2 infections in Chinese mainland. As the number of infected people increased, the mutation probability of SARS-CoV-2 is also raised. Therefore, it is of great importance to monitor SARS-CoV-2 variants and its mutations in China. In this current study, 665 SARS-CoV-2 genomes from China deposited in the public database were used to analyze the proportion of different variants; to determine the composition of variants in China across different provinces; and analyze specific mutation frequency, focusing on 12 immune escape residues. The results showed that no new mutations were generated on the 12 immune escape residues. The evolutionary analysis of the BF.7 variant circulating in China showed that there is an independent evolutionary branch with unique mutation sites, officially named BF.7.14 by PANGO. This variant may have been imported from Russia to Inner Mongolia at the end of September 2022 and continued its spread in China. The evolutionary analysis of BA.5.2 variant shows that the variant is composed of two sub-variants, named BA.5.2.48 and BA.5.2.49 by PANGO, respectively. This variant may have been imported from abroad to Beijing at the beginning of September 2022 and formed two sub-variants after domestic transmission. Finally, this study showed that current epidemic variants in China were already circulating in other countries, and there were no additional mutations on immune escape residues that could pose a threat to other countries.
2022年12月7日,中国调整了公共卫生防控措施,中国大陆出现了广泛的新型冠状病毒感染。随着感染人数的增加,新型冠状病毒的突变概率也有所提高。因此,监测中国大陆新型冠状病毒变体及其突变情况至关重要。在本研究中,使用公共数据库中存放的来自中国的665个新型冠状病毒基因组,分析不同变体的比例;确定中国不同省份变体的组成;并分析特定突变频率,重点关注12个免疫逃逸位点。结果显示,12个免疫逃逸位点未产生新的突变。对在中国流行的BF.7变体的进化分析表明,存在一个具有独特突变位点的独立进化分支,被PANGO正式命名为BF.7.14。该变体可能于2022年9月底从俄罗斯传入内蒙古,并在中国继续传播。对BA.5.2变体的进化分析表明,该变体由两个亚变体组成,PANGO分别将其命名为BA.5.2.48和BA.5.2.49。该变体可能于2022年9月初从国外传入北京,并在国内传播后形成了两个亚变体。最后,本研究表明,中国目前的流行变体已在其他国家传播,且免疫逃逸位点上没有可能对其他国家构成威胁的额外突变。